Recruitment for Alzheimer’s Disease study now open at Oxford Health Clinical Research Facility (OH CRF)

Alzheimer’s Disease is a type of dementia in which abnormal proteins, called beta-amyloid and tau, accumulate in the brain and damage nerve cells. People with Alzheimer’s Disease often have trouble thinking, speaking, remembering things, and performing their daily activities. This condition is common in older people and gets worse over time.

Recruitment for Alzheimer’s Disease study now open at Oxford Health Clinical Research Facility (OH CRF)

The purpose of the CELIA study is to look at whether a drug called BIIB080 can help people with  Alzheimer’s Disease , how safe it is, and how the body handles taking it (known as tolerability). The study is being carried out in around 140 sites in approximately 18 countries around the world. Across all sites, about 735 participants will take part in the study.

The CELIA study in Oxford is a collaboration between Oxford Health Clinical Research Facility (OH CRF)Oxford University Hospitals Clinical Research Facility (OUH CRF) and Oxford University Hospitals  Pharmacy and Neurology departments and  is now open for recruitment.

Part of the trial will be carried out at the at the NIHR OH CRF.

The study team are looking for participants for the CELIA study who meet the following criteria:

  • have been diagnosed with mild cognitive impairment due to Alzheimer’s Disease
  • have been diagnosed with mild Alzheimer’s Disease or dementia
  • between 50 and 80 years of age who are diagnosed with Alzheimer’s Disease

All participants must have a study partner who is available to accompany them to study site visits and provide information about the participant to the study doctor. The study partner can be a family member or legally authorised representative (LAR) that is responsible for the participant’s care.

Participation in the study will last for 105 weeks (about 2 years) in total.

Participation, includes up to 18 study site visits and up to 15 follow-up telephone calls during 3 distinct periods:

• Screening period (about 9 weeks)
• Treatment period (76 weeks or approximately 18 months)
• Follow-up period (20 weeks or 5 months)

Recruitment for the CELIA study has started and runs until November 2025.

If you or someone you know would like further information about the CELIA study or would like to participate, please contact the Oxford Health NHS Foundation Trust Memory and Cognition Research Development Team by email at

How do you rate this page?

Thank you for your feedback

Follow us on social media to stay up to date

We are sorry you did not find this page helpful

Tell us how we can improve this page

Published: 26 February 2024